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predictor of reduced survival after valve replacement (14).
Furthermore, thromboembolic and bleeding events are not
equivalent in terms of mortality risk. The one-year survival
after ischemic stroke is about 80%, whereas the one-year
survival after intracerebral hemorrhage is only about 20%
(15).
The paper of Vink et al. (1) reinforces the view of the
Dutch Thrombosis Service since the mid-1980s that all
mechanical valve patients should have an INR of 3.0 to 4.5,
(16) However, it is scientifically unsound in its methodol-
ogy, ignores evidence for a contrary view, including RCTs
and current guidelines (2,4,17), and takes a big step back-
ward from the modern practice that is based on individual
risk stratification and risk-adjusted intensity of anticoagu-
lation. We believe that their recommendations should not
be followed.
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REPLY
We appreciate the comments regarding our article (1). Dr.
Takkenberg and colleagues have calculated mortality rates
of the thromboembolic and bleeding complications and
found no differences between high-intensity and low-
intensity therapy with vitamin K antagonists. Unfortu-
nately, only approximately 50% of the included studies
reported on mortality rates. As a result, the mortality event
rate is too low to draw any statistically confident conclusion.
Therefore, it remains uncertain whether the results of this
small number of studies would be representative for the total
mortality rate of all studies analyzed in our meta-analysis.
Dr. O’Kane raised an important point about the target
international normalized ratio (INR). We agree that it is
more sound to evaluate the achieved INR rather than the
target INR. However, as already mentioned in our article,
most reports used for our analysis were based on an
intention-to-treat INR range. Furthermore, Dr. O’Kane
recommends an INR between 2.5 and 3.0 based on a
single-center observational study, which unfortunately lacks
information on the time spent in the target range and the
achieved INR. In addition, a part of the study population in
this study received dipyramidole in combination with vita-
min K antagonists, which increased the risk of bleeding
complications (2).
Drs. Butchart and Gohlke-Bärwolf are confused when
they state that meta-analyses can be performed only on
randomized controlled trials. It should be clarified that
meta-analysis is a statistical method defined as the quanti-
tative analysis of two or more independent studies to
integrate the findings. Studies used for meta-analysis can
vary from randomized trials, non-randomized trials, or
observational studies, and even from more than one of these
types of studies (3).
Furthermore, they postulate that the reported thrombo-
embolic rates are influenced by definitions, data collection
methods, and patient characteristics. In our study, all events
were analyzed according to the guidelines for reporting
morbidity and mortality after cardiac valvular operations of
Edmunds et al. (4), which minimize the potential for bias.
Mean age at valve implantation and gender did not differ
between the groups. Other characteristics were not specified
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and, therefore, it is unknown whether these factors influ-
ence the outcome.
We agree that retrospective conversion of prothrombin
time ratios to an INR has the potential to introduce errors.
However, the conversion of the results of the thrombotest
and prothrombin time ratios to an INR was required in only
7 of 35 studies. Furthermore, for all 7 of the studies, the ISI
value of the thromboplastin reagent used was known, as
indicated in our article.
Surprisingly, Drs. Butchart and Gohlke-Bärwolf state
that we did not acknowledge five randomized trials com-
paring different intensities of anticoagulation. However,
three of these five studies were excluded according to our
predefined exclusion criteria (5–7) and are listed on the web
site (www.cardiosource.com/jacc.html). The fourth study
did not fulfill the inclusion criteria, because the study
included patients with tissue valves (8) and the fifth study
has been presented only in part in a supplement journal and
was therefore not retrieved by the Pubmed search (9). Drs.
Butchart and Gohlke-Bärwolf conclude that four of these
randomized trials showed a higher incidence of bleeding
with higher intensity of anticoagulation. We disagree with
this conclusion because a thorough analysis of these studies
reveals that only one of the randomized trials (in patients
with mechanical valves) comparing low-intensity versus
high-intensity vitamin K antagonist therapy showed a
significant increased risk of bleeding in the high-intensity
group (7). It should be emphasized that the patients in this
study received dipyramidole and aspirin in addition to
vitamin K antagonists.
In conclusion, our analysis, including a total of 23,145
patients followed for more than 100,000 patient-years,
shows that the total number of tromboembolic and bleeding
events is lowest with high-intensity vitamin K antagonist
therapy. The absolute incidences of thromboembolism and
bleeding are low, and therefore it would be impossible to
perform a large prospective trial comparing different inten-
sities of vitamin K antagonist therapy. Therefore, combin-
ing the results of several studies through the techniques of
meta-analysis can provide stronger evidence for or against a
treatment effect than one can derive from any of the
individual studies.
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